The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 334:155-160 January 18, 1996 Number 3
NextNext

A Comparison of Fecal Occult-Blood Tests for Colorectal-Cancer Screening
James E. Allison, M.D., Irene S. Tekawa, M.A., Laura J. Ransom, M.S., and Alyn L. Adrain, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Letters
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Hemoccult II, a widely used guaiac test for fecal occult blood, has a low sensitivity for detecting colorectal neoplasms in asymptomatic patients at average risk. In such patients, the performance characteristics of screening tests developed to improve on Hemoccult II are not known.

Methods A set of three fecal occult-blood tests — Hemoccult II; Hemoccult II Sensa, a more sensitive guaiac test; and HemeSelect, an immunochemical test for human hemoglobin — was mailed to all patients 50 years of age or older who were scheduled for personal health appraisals at the Kaiser Permanente Medical Center in Oakland, California. The performance of each test and of a combination test (HemeSelect to confirm positive Hemoccult II Sensa results) was evaluated by identifying screened patients who had colorectal neoplasms (carcinoma or a polyp >1 cm in diameter) in the two years after screening.

Results Of the 10,702 eligible patients, 8104 (75.7 percent) had at least one interpretable sample and were screened on the basis of at least one test; 96 percent of these patients had complete two-year follow-up. The sensitivity of the tests for detecting carcinoma was lowest with Hemoccult II (37.1 percent; 95 percent confidence interval, 19.7 to 54.6 percent), intermediate with the combination test (65.6 percent; 95 percent confidence interval, 47.6 to 83.6 percent) and with HemeSelect (68.8 percent; 95 percent confidence interval, 51.1 to 86.4 percent), and highest with Hemoccult II Sensa (79.4 percent; 95 percent confidence interval, 64.3 to 94.5 percent). The specificity for detecting carcinoma was 86.7 percent with Hemoccult II Sensa, 94.4 percent with HemeSelect, 97.3 percent with the combination test, and 97.7 percent with Hemoccult II. HemeSelect and the combination test detected more colorectal carcinomas and polyps than Hemoccult II, with only slight increases in the number of colonoscopies needed.

Conclusions HemeSelect and a combination test in which HemeSelect is used to confirm positive Hemoccult II Sensa results improve on Hemoccult II in screening patients for colorectal carcinoma.


Source Information

From the Department of Medicine, Kaiser Permanente Medical Center (J.E.A., A.L.A.); and the Division of Research, Kaiser Permanente Medical Care Program (I.S.T., L.J.R.) — both in Oakland, Calif. Presented in part at the 93rd Annual Meeting of the American Gastroenterological Association, San Francisco, May 9–15, 1992, and at the 94th Annual Meeting, Boston, May 15–21, 1993.

Address reprint requests to Dr. Allison at the Department of Medicine, Kaiser Permanente Medical Center, 280 W. MacArthur Blvd., Oakland, CA 94611-5693.

Full Text of this Article


Related Letters:

Improving the Fecal Occult-Blood Test
Allison J. E., Tekawa I. S., Ransom L. J., Adrain A. L., Ransohoff D. F., Lang C. A.
Extract | Full Text  
N Engl J Med 1996; 334:1607-1608, Jun 13, 1996. Correspondence

Occult Gastrointestinal Bleeding in Celiac Sprue
Duane W. C., Heneghan M. A., McCarthy C. F., Fine K. D.
Extract | Full Text  
N Engl J Med 1996; 335:752-753, Sep 5, 1996. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.